Gfr Change

Introduction

The glomerular filtration rate (GFR) is a key indicator of kidney function, representing the volume of fluid filtered from the blood by the glomeruli per unit of time. While a single GFR provides a snapshot of kidney health, the GFR change over time, often referred to as eGFRchange, offers critical insights into the dynamic process of kidney function decline or improvement. This metric is typically calculated by comparing estimated GFR (eGFR) values obtained from at least two serum creatinine measurements taken years apart, with a positive value indicating a decline in kidney function and a negative value an increase.^[1]Several specific phenotypes are used to characterize kidney function decline, including the continuous annual change in eGFR (eGFRchange), rapid decline (defined as an annual eGFR decline of 3 ml/min/1.73m² or more), and incident chronic kidney disease (CKD), which includes cases where eGFR drops below 60 ml/min/1.73m² (CKDi) or with an additional 25% decline from baseline (CKDi25).^[1]

Biological Basis

The kidneys play a vital role in filtering waste products from the blood, maintaining electrolyte balance, and regulating blood pressure. A decline in GFR signifies a reduction in the kidneys’ ability to perform these essential functions. While baseline kidney function is influenced by various factors, research indicates that there are unique genetic contributions to the rate of renal function decline, distinct from those affecting a single GFR.^[1] The heritability of eGFR change has been estimated to be approximately 38% in individuals of European descent, suggesting a significant genetic component influencing how kidney function changes over time.^[1] This heritability provides a strong rationale for investigating specific genetic variants associated with kidney function decline.

Clinical Relevance

Monitoring GFR change is clinically crucial for identifying individuals at risk of progressive kidney disease and its associated complications. A rapid decline in kidney function is strongly linked to adverse health outcomes, including increased risk of cardiovascular disease and higher mortality rates, particularly in older adults.^[2]Early identification of individuals experiencing significant eGFR decline allows for timely interventions, such as lifestyle modifications, medication adjustments, and management of co-morbidities, which can slow progression to end-stage renal disease (ESRD). The rate of kidney function decline can also vary depending on the baseline eGFR, highlighting the need for tailored clinical approaches.^[1]

Social Importance

Chronic kidney disease (CKD) is a global public health challenge, affecting millions worldwide.^[3] The prevalence of CKD, defined as eGFR less than 60 ml/min/1.73m², can range significantly across populations.^[1]Understanding the genetic factors that influence GFR change can lead to improved risk prediction, personalized medicine approaches, and the development of novel therapeutic strategies to prevent or slow the progression of CKD. By elucidating the genetic underpinnings of kidney function decline, researchers aim to reduce the burden of CKD and its severe health consequences on individuals and healthcare systems globally.

Phenotypic Definition and Imprecision

The precise definition and consistent of kidney function decline pose significant challenges that may have attenuated the statistical power of the studies to identify genetic associations. There is no universally agreed-upon standard definition for renal function decline, and while the studies utilized several guideline-featured definitions, this inherent variability can introduce heterogeneity across analyses. Furthermore, the reliance on a minimum of two serum creatinine measurements, and often only two in total, may not fully capture the complex, potentially non-linear trajectories of kidney function change over extended periods, alongside day-to-day physiological fluctuations in GFR.^[1] GFR estimation equations, such as the MDRD Study Equation employed, are known to have limitations regarding precision, particularly at eGFR values above 60 ml/min/1.73m2.^[1] This imprecision can lead to misclassification of individuals and obscure true rates of decline, especially in general population cohorts where many participants have eGFR within this less precise range. Although efforts were made to calibrate serum creatinine measurements to national standards to mitigate inter-assay variability.^[4] the observed heterogeneity in study designs, including a wide range of follow-up durations from 2.0 to 22.2 years, further contributes to the imprecision of the derived kidney function decline phenotypes.^[1]

Generalizability and Cohort Specificity

A significant limitation of the studies is their primary focus on individuals of European descent, which restricts the direct generalizability of the findings to other ancestral populations. The genetic architecture influencing kidney function and its decline can vary substantially across different ethnic groups, indicating a need for future research in diverse populations to confirm and expand these identified associations.^[5]Moreover, while the research provides novel insights into mechanisms of kidney function decline within general population cohorts, these findings may not be directly transferable to cohorts specifically enriched for chronic kidney disease (CKD).^[1] An unexpected observation in several general population cohorts was that the subgroup with baseline CKD (defined as eGFR < 60 ml/min/1.73m2) exhibited a mean increase in eGFR over time, irrespective of follow-up length.^[1]This suggests that in such population-based studies, a baseline eGFR below 60 ml/min/1.73m2 may not consistently represent progressive CKD with active disease, but rather stable disease or imprecise GFR estimation. This potential mischaracterization of the CKD subgroup within general populations highlights a cohort-specific bias that could impact the interpretation of genetic associations related to CKD progression.

Statistical Power, Replication Challenges, and Unexplained Heritability

Despite the substantial sample size achieved through meta-analysis across multiple cohorts, challenges related to statistical power for detecting genetic effects of modest size were evident. Only one locus,rs12917707 at UMOD, achieved genome-wide significance in the combined stage 1 and stage 2 meta-analysis, while two novel loci (CDH23 and GALNTL5/GALNT11) showed only suggestive evidence of association.^[1] The lack of significant association for these novel loci in independent replication cohorts, such as the CRIC study, further underscores the difficulties in consistently replicating findings, potentially due to differing cohort characteristics or insufficient statistical power in specific replication sets.^[1] The heritability of eGFR change was estimated to be 38% in the general population, indicating a considerable genetic contribution to this trait.^[1] However, the genetic variants identified in these studies explain only a fraction of this heritability, pointing to a substantial “missing heritability” gap. This suggests that numerous other genetic factors, including rare variants, structural variations, or complex gene-gene and gene-environment interactions, remain undiscovered. Further extensive research utilizing expanded datasets and sophisticated analytical and functional models is necessary to comprehensively unravel the genetic landscape underlying the initiation and progression of CKD.^[1]

Variants

Genetic variations play a crucial role in influencing an individual’s kidney function and its decline over time. Genome-wide association studies (GWAS) have identified several single nucleotide polymorphisms (SNPs) associated with changes in estimated glomerular filtration rate (eGFR), a key measure of kidney health. These variants often lie within or near genes that are fundamental to renal physiology or broader cellular processes.

One prominent variant, rs12917707 , is located in the UMOD locus, encompassing the UMOD and PDILT genes. The UMOD gene encodes uromodulin, also known as Tamm-Horsfall protein, which is the most abundant protein in mammalian urine and is produced exclusively by the kidney’s thick ascending limb of the loop of Henle. Uromodulin plays diverse roles in renal physiology, including protection against urinary tract infections, modulation of innate immunity, and regulation of kidney stone formation. The minor T allele of rs12917707 has been significantly associated with an increase in eGFR over time, suggesting a protective effect against kidney function decline. This association reached genome-wide significance in meta-analyses of individuals of European descent, highlighting UMOD’s established role in kidney health.^{[1], [6]} Another significant variant, rs875860 , is an intronic SNP within the CDH23gene, which encodes Cadherin 23. This protein is a large glycoprotein belonging to the cadherin superfamily, primarily known for its role in cell-to-cell adhesion and mechanosensory transduction in the inner ear, where mutations can cause deafness and Usher syndrome. In the context of kidney health,rs875860 has shown suggestive association with eGFR change in individuals already diagnosed with chronic kidney disease (CKD). Functional studies in zebrafish models, where thecdh23 gene was knocked down, indicated an increased susceptibility to nephrotoxic insults, suggesting a protective role for the gene in maintaining kidney integrity under stress.^[1] Beyond these well-studied variants, several other genetic loci are implicated in kidney function. For instance, rs17033285 is associated with LINC01121, a long intergenic non-coding RNA. LncRNAs are crucial regulators of gene expression, influencing processes from chromatin remodeling to transcriptional control, and their dysregulation can impact cell differentiation and organ function, including that of the kidney. Similarly, rs4917601 is located near ADRA2A and BTBD7P2. ADRA2A encodes the alpha-2A adrenergic receptor, which is vital for regulating blood pressure, renal hemodynamics, and electrolyte balance within the kidneys, thereby directly affecting GFR. Variations in such genes could modulate renal function and contribute to the observed heritability of eGFR decline, which is estimated at 38% in the general population.^{[1], [7]} Further genetic variations include rs9762450 in MARCHF1 and rs12057071 in ELAVL2. MARCHF1 encodes an E3 ubiquitin ligase, an enzyme critical for targeting specific proteins for degradation. This process is fundamental to cellular homeostasis, immune regulation, and the removal of damaged proteins, all of which are essential for maintaining kidney health and responding to injury. ELAVL2 produces an RNA-binding protein involved in regulating mRNA stability and translation, particularly in neurological development, but its widespread expression suggests broader roles in cellular resilience and repair mechanisms across various tissues, including the kidney. Lastly, rs918378 is found near HMHB1 and RN7SL87P, which are pseudogenes. While pseudogenes typically do not encode functional proteins, they can exert regulatory functions, such as acting as microRNA sponges or influencing the expression of their protein-coding counterparts, potentially impacting pathways relevant to kidney function and decline.^{[1], [6]}

Key Variants

RS ID	Gene	Related Traits
rs12917707	UMOD - PDILT	chronic kidney disease, serum creatinine amount gfr change chronic kidney disease urinary system trait urinary uromodulin
rs17033285	LINC01121	gfr change
rs4917601	ADRA2A - BTBD7P2	gfr change
rs9762450	MARCHF1	gfr change
rs12057071	ELAVL2	gfr change
rs918378	HMHB1 - RN7SL87P	gfr change
rs875860	CDH23	gfr change

Defining Annualized Glomerular Filtration Rate Change

The continuous phenotype ‘eGFRchange’ serves as a crucial measure for quantifying the annual rate of alteration in kidney function. Operationally, it is calculated by subtracting the estimated Glomerular Filtration Rate (eGFR) at a follow-up from the eGFR at baseline, then dividing this difference by the number of years elapsed between the two measurements. A positive value for eGFRchange explicitly indicates a decline in kidney function over time, while a negative value signifies an improvement or increase in kidney function annually. This precise definition allows for a continuous, dimensional assessment of kidney health trajectories, expressed in milliliters per minute per 1.73 square meters of body surface area per year (ml/min/1.73m2 per year).

The of eGFRchange relies on serial serum creatinine measurements, typically using two time points with the longest available follow-up for each individual. The GFR is estimated from serum creatinine using standardized equations, such as the four-variable Modification of Diet in Renal Disease (MDRD) Study Equation. To ensure consistency and comparability across different studies and laboratories, both baseline and follow-up serum creatinine values are calibrated to nationally representative standards, such as those from the US National Health and Nutrition Examination Study (NHANES).^[4] Furthermore, extreme eGFR values are often capped, with values below 15 ml/min/1.73m2 set to 15, and those above 200 ml/min/1.73m2 set to 200, to manage the limitations of eGFR estimation at very low or very high ranges.

Categorical Phenotypes of Kidney Function Decline

Beyond the continuous eGFRchange, several dichotomous phenotypes are established to classify distinct patterns of kidney function decline with varying clinical implications, offering a categorical approach to disease classification and severity gradation. These include “Rapid Decline,” “Incident CKD” (CKDi), and a more stringent “Incident CKD with 25% decline” (CKDi25). These classifications provide clear diagnostic criteria and cut-off values for identifying individuals at different levels of risk or disease progression.

“Rapid Decline” is defined by a significant annual reduction in kidney function, with cases characterized as individuals experiencing an eGFR decline of 3 ml/min/1.73 m2 or more per year.^[8] Conversely, controls are those with an annual eGFR decline less than this threshold. This classification is clinically significant for identifying individuals at the highest risk for adverse outcomes.^[8]“Incident CKD” (CKDi) captures individuals who transition into chronic kidney disease (CKD) during the follow-up period; cases are defined as participants with a baseline eGFR of 60 ml/min/1.73m2 or greater, whose eGFR subsequently falls below 60 ml/min/1.73m2 at follow-up, thereby reaching CKD stage 3 or higher.^[9] Controls for CKDi maintain an eGFR of 60 ml/min/1.73m2 or higher at both baseline and follow-up. The “Incident CKD with 25% decline” (CKDi25) applies a more stringent criterion, requiring not only the CKDi definition to be met but also an additional decline of at least 25% in eGFR from baseline to follow-up, specifically selecting individuals who experience a substantial and clinically significant reduction in kidney function.

Contextualizing and Analysis through Stratification

The understanding and analysis of kidney function change are often refined by considering the individual’s baseline kidney health, acknowledging that the rate of decline can differ significantly depending on the initial eGFR level. To account for this, analyses of eGFRchange and other decline phenotypes are frequently stratified. Common strata include the “overall sample” (eGFRchange overall), individuals with an eGFR of 60 ml/min/1.73m2 or greater at baseline (eGFRchange noCKD), and those with an eGFR less than 60 ml/min/1.73m2 at baseline (eGFRchange withCKD). This stratified approach allows for a more nuanced investigation into the mechanisms underlying kidney function change in different populations, for example, distinguishing decline trajectories in individuals without pre-existing CKD from those already living with the condition.

Furthermore, specific dichotomous traits like “Rapid Decline” may also be analyzed in an overall sample (Rapid Decline overall) or specifically among those without baseline CKD (Rapid Decline noCKD). Such stratification acknowledges that the prevalence and clinical significance of rapid decline may vary across different baseline kidney function statuses, sometimes precluding analysis in certain groups due to insufficient case numbers. This careful operationalization and contextualization of kidney function change measurements are critical for robust research, allowing for targeted insights into the genetic and environmental factors influencing renal health across diverse populations.

Assessment of GFR Change through Serial Measurements

The primary method for diagnosing and characterizing changes in glomerular filtration rate (GFR) relies on serial measurements of serum creatinine over time. This approach allows for the calculation of annual eGFR change, which is determined by subtracting the estimated GFR (eGFR) at follow-up from the baseline eGFR and then dividing by the duration of follow-up in years. A positive value for eGFR change indicates a decline in kidney function, while a negative value signifies an increase. For accurate and consistent eGFR estimation, the four-variable MDRD Study Equation is commonly employed, and serum creatinine measurements are carefully calibrated to national standards, such as those from the US National Health and Nutrition Examination Study (NHANES) data, to minimize inter-laboratory variability.^[4] Several distinct phenotypes are used to categorize and assess different patterns of kidney function decline, each with specific diagnostic criteria and clinical implications. “Rapid Decline” is defined as an annual eGFR reduction of 3 ml/min/1.73 m2 or more, identifying individuals at higher risk of adverse outcomes. “Incident CKD” (CKDi) applies to participants whose baseline eGFR is 60 ml/min/1.73 m2 or higher but subsequently declines to less than 60 ml/min/1.73 m2 at follow-up. A more stringent criterion, “CKDi25,” further restricts incident CKD cases to those experiencing an additional eGFR decline of at least 25% from baseline, thereby selecting individuals who reach CKD stage 3 after a substantial reduction in kidney function.^[1]

Genetic and Molecular Markers in Kidney Function Decline

Genetic predisposition plays a significant role in the trajectory of kidney function, with the heritability of eGFR change estimated to be approximately 38% in the general population of European descent.^[1]Genome-wide association studies (GWAS) serve as powerful diagnostic tools for identifying specific genetic variants, or single nucleotide polymorphisms (SNPs), that are associated with the rate of kidney function change. These studies have revealed that certain loci, such as thers12917707 SNP at the _UMOD_ gene, are significantly linked to an increase in eGFR over time, offering insights into genetic factors that may influence kidney stability or improvement.^[1] Beyond established genetic associations, GWAS has also identified novel molecular markers that show suggestive associations with distinct kidney function decline phenotypes. For example, the rs875860 SNP within the _CDH23_gene has been suggestively associated with eGFR change in individuals who already have chronic kidney disease (CKD) at baseline. Similarly, thers1019173 SNP located in the _GALNTL5_/_GALNT11_ gene region has shown a suggestive association with “Rapid Decline”.^[1] The identification of these genetic loci, alongside others such as _MEOX2_, _IL1RAP_, _NPPA_, and _HPCAL1_, enhances the understanding of the genetic underpinnings of kidney function decline, potentially aiding in risk stratification and the development of targeted interventions.^[1]

Challenges and Refinements in Diagnosing GFR Change

The accurate diagnosis and characterization of GFR change are complicated by several methodological challenges and inherent imprecisions. A key issue is the lack of a universally accepted standard definition for renal function decline, which can lead to inconsistencies in diagnosis and reporting across different clinical and research contexts.^[1] Moreover, relying solely on two serum creatinine measurements over an extended period may not fully capture the true trajectory of kidney function, as changes in renal function can be non-linear, and day-to-day variations in GFR can introduce considerable imprecision into the assessment.^[1] Further diagnostic complexities arise from the limitations of eGFR estimation equations, which are known to be less precise, particularly when GFR values are above 60 ml/min/1.73 m2.^[1]This imprecision can obscure the detection of subtle declines in early stages of kidney disease. Additionally, heterogeneity in study designs, including varied lengths of follow-up intervals, can impact the robustness of observed kidney function decline phenotypes. It is also important to consider that a baseline eGFR below 60 ml/min/1.73m2 in certain CKD subgroups might not always indicate progressive disease but could represent stable kidney function or an imprecise eGFR estimation, highlighting the continuous need for improved diagnostic methodologies and more extensive datasets.^[1]

Understanding Glomerular Filtration Rate Dynamics

Glomerular filtration rate (GFR) serves as a crucial indicator of kidney function, reflecting the rate at which blood is filtered by the glomeruli in the kidneys. Since direct of GFR is complex, estimated GFR (eGFR) is commonly used, calculated from serum creatinine levels, typically employing equations like the MDRD Study Equation. Monitoring the change in eGFR over time is vital for assessing kidney health, as a decline can indicate progressive kidney disease and increased risk of adverse health outcomes.^[2] The annual change in eGFR, often termed ‘eGFRchange’, is calculated by subtracting follow-up eGFR from baseline eGFR and dividing by the years of follow-up, where a positive value signifies a decline in kidney function.^[1]Beyond continuous eGFR change, specific decline phenotypes are used to characterize the severity and clinical implications of kidney function reduction. These include “Rapid Decline,” defined as an annual eGFR reduction of 3 ml/min/1.73m2 or more, which is associated with increased cardiovascular risk and mortality.^[8]“Incident CKD” (CKDi) identifies individuals who develop Chronic Kidney Disease (CKD) stage 3 (eGFR < 60 ml/min/1.73m2) from a baseline eGFR of 60 ml/min/1.73m2 or higher. A more stringent definition, “CKDi25,” additionally requires at least a 25% decline in eGFR from baseline. These distinct phenotypes allow for a nuanced understanding of kidney disease progression and assist in identifying individuals with varying risks and clinical needs.^[1]

Genetic Architecture of Kidney Function Decline

Genetic factors play a significant role in determining the trajectory of kidney function, with the heritability of eGFR change estimated at 38% in the general population.^[1] This substantial heritable component provides a strong rationale for identifying specific genetic variants associated with the decline in kidney function. Genome-wide association studies (GWAS) have been instrumental in uncovering genetic loci linked to eGFR and CKD, revealing that there are unique genetic contributions to renal function decline that are distinct from those influencing baseline renal function.^[6] Research has identified several genetic loci associated with eGFR decline phenotypes. The UMOD locus, specifically rs12917707 , has shown genome-wide significant association with an increase in eGFR over time, suggesting its protective or regulatory role in maintaining kidney function.^[1] Additionally, two novel genetic loci, CDH23 (rs875860 ) and GALNTL5/GALNT11 (rs1019173 ), have demonstrated suggestive associations with eGFR decline, particularly in individuals with CKD or those experiencing rapid decline. These findings highlight the complex genetic architecture underlying the variability in kidney function decline, indicating that multiple genes and pathways contribute to an individual’s susceptibility to progressive kidney disease.^[1]

Key Molecular Players and Cellular Functions in Renal Health

The genes identified through genetic studies are implicated in various molecular and cellular processes crucial for kidney health. UMODencodes uromodulin, a protein exclusively produced in the kidney’s thick ascending limb of Henle, known to play a role in urinary tract infection prevention and kidney stone formation. Its association with eGFR change suggests its broader involvement in maintaining overall kidney function and protecting against decline.^[1] Mutations or variants in UMOD can impact its function, potentially affecting kidney’s ability to filter and excrete waste products effectively.

The GALNTL5/GALNT11 locus involves genes with roles in glycosylation, a critical post-translational modification of proteins. GALNT11 (Polypeptide N-acetylgalactosaminyltransferase 11) is a glycosyl transferase that initiates O-linked oligosaccharide biosynthesis, a process essential for cell signaling and adhesion.^[1] Studies in zebrafish indicate that GALNT11 modulates Notch1 signaling, which is important for establishing the balance between motile and immotile cilia, and is expressed in the developing kidney. Functional validation suggests that while GALNT11 may not be essential for kidney development, it confers protection against nephrotoxic insults, highlighting its role in renal resilience.^[1] GALNTL5 (Polypeptide N-acetylgalactosaminyltransferase-like protein 5) is also a putative glycosyltransferase, implying a related function in cellular processes that could impact kidney integrity. The CDH23 gene, associated with eGFR change in individuals with CKD, encodes Cadherin 23, a cell adhesion molecule. Its intronic variant suggests a potential regulatory role affecting cellular interactions within the kidney, which could influence tissue integrity and response to injury.^[1]

Pathophysiological Progression of Chronic Kidney Disease

The interplay of genetic predispositions and various physiological stressors can disrupt renal homeostasis, leading to the pathophysiological progression of kidney function decline. The variability in the rate of eGFR decline is observed across diverse populations, including healthy individuals and those already diagnosed with CKD.^[10]This variability suggests that while some individuals may experience a slow, stable decline, others face a rapid progression towards end-stage renal disease. Genetic background, as shown in animal models, significantly affects the progression of CKD, supporting the idea that specific genetic variants contribute to an individual’s susceptibility or resilience to kidney damage.^[1]Clinical observations also indicate that a baseline eGFR below 60 ml/min/1.73m2 does not always signify active, progressive CKD; in some cohorts, this subgroup even shows a mean increase in eGFR over time. This phenomenon underscores the complexity of accurately defining and tracking kidney function decline, as imprecise GFR estimation or stable disease could be misconstrued as progressive CKD.^[1]Understanding the molecular and genetic underpinnings of these diverse trajectories is crucial for developing targeted interventions that can halt or slow the progression of kidney disease, ultimately improving patient outcomes.

Genetic Basis of Kidney Function Decline

The decline in kidney function, often quantified as a change in estimated glomerular filtration rate (eGFR), is a complex trait influenced by genetic factors. Research indicates that the heritability of eGFR change is approximately 38% in individuals of European descent, providing a strong rationale for identifying specific genetic variants involved.^[1] Genome-wide association studies (GWAS) have successfully identified several loci significantly associated with longitudinal changes in kidney function. Key genetic loci linked to eGFR change or rapid decline include UMOD, CDH23, and the GALNTL5/GALNT11region, highlighting specific molecular pathways that contribute to kidney health and disease progression.^[1] These genetic insights provide a foundation for understanding the underlying mechanisms governing the rate of kidney function loss.

Glycosylation and Signaling Pathways in Renal Physiology

A critical mechanism identified involves the genes GALNTL5 and GALNT11, which are associated with rapid eGFR decline.^[1] GALNTL5 encodes a putative polypeptide N-acetylgalactosaminyltransferase-like protein 5, while GALNT11 encodes a polypeptide N-acetylgalactosaminyltransferase 11, both involved in the initial steps of O-linked oligosaccharide biosynthesis.^[1] This process, a form of post-translational protein modification, is crucial for protein structure and function, impacting various cellular processes. Furthermore, GALNT11 has been shown to modulate Notch1 signaling, a fundamental intracellular signaling cascade involved in cell fate determination, development, and tissue homeostasis.^[1] The modulation of Notch1 signaling by GALNT11 is particularly relevant to kidney function, as it influences the crucial balance between motile and immotile cilia, which are essential for proper kidney development and function.^[1] Functional studies in zebrafish have demonstrated that while galnt11 may not be essential for kidney development itself, it plays a protective role against nephrotoxic insults, suggesting a mechanism by which this glycosyl transferase contributes to renal resilience and prevents rapid decline in the face of stress.^[1] This highlights the interplay between metabolic pathways (biosynthesis of glycans), signaling cascades, and the overall physiological integrity of the kidney.

Cell Adhesion and Nephron Protection Mechanisms

The CDH23gene, encoding Cadherin 23, represents another significant locus associated with eGFR change, particularly in individuals with pre-existing chronic kidney disease (CKD).^[1]Cadherins are a class of cell adhesion molecules that are vital for maintaining tissue structure and cell-cell interactions. The identification of an intronic single nucleotide polymorphism (SNP) withinCDH23 suggests its regulatory importance in kidney function decline.^[1] Further functional investigations involving the knockdown of CDH23 in zebrafish models revealed that its absence renders the nephron susceptible to nephrotoxic challenges.^[1] This indicates that CDH23 likely plays a protective role in maintaining the structural integrity or resilience of kidney cells, potentially through its involvement in cell adhesion or other regulatory mechanisms that safeguard nephron function under stress. Dysregulation of such a protective mechanism could contribute to the progressive loss of kidney function observed in CKD.

Integrated Molecular Networks in Chronic Kidney Disease Progression

The UMOD locus, encoding Uromodulin, is a well-established genetic factor strongly associated with kidney function and incident CKD.^[6] This locus has now also shown genome-wide significant association with the annual change in eGFR.^[1] The consistent involvement of UMOD, alongside novel loci like CDH23 and GALNTL5/GALNT11, underscores a systems-level integration of diverse molecular pathways contributing to the complex phenotype of kidney function decline.^[1] These genes likely participate in a hierarchical regulatory network where their individual contributions, through mechanisms such as protein modification (glycosylation), cell adhesion, and modulation of signaling cascades (Notch1), converge to influence the overall health and decline trajectory of the kidney.

Pathway crosstalk and network interactions among these and other yet-to-be-identified genes contribute to the emergent properties of kidney function and its susceptibility to decline.^[1] Dysregulation within these integrated networks can lead to pathway dysregulation, manifesting as accelerated eGFR decline or incident CKD.^[1]Understanding these disease-relevant mechanisms, including potential compensatory responses and points of vulnerability, is crucial for identifying novel therapeutic targets to mitigate the progression of kidney disease.

Prognostic and Predictive Utility of Kidney Function Change

Measuring the change in estimated glomerular filtration rate (eGFR) over time holds significant prognostic value, serving as a critical indicator for predicting adverse clinical outcomes and disease progression. A rapid decline in kidney function, often defined as an annual eGFR decline of 3 ml/min/1.73m2 or more, is strongly associated with an increased risk of mortality in older adults and heightened cardiovascular risk.^{[8], [11]}Studies have consistently demonstrated that even a one-year change in kidney function is linked to increased mortality risk and a greater likelihood of progressing to end-stage renal disease (ESRD).^[12]This predictive power extends to broader health implications, as changes in eGFR are also associated with coronary heart disease and overall mortality.^[2]Furthermore, specific decline phenotypes, such as incident chronic kidney disease (CKDi) or a more stringent definition involving at least a 25% eGFR decline (CKDi25), identify individuals who reach CKD stage 3 after a substantial kidney function reduction.^[1] The identification of genetic loci, such as UMOD, which is associated with kidney function change, incident CKD, and ESRD, further underscores the long-term prognostic implications of monitoring eGFR trajectories.^[1] These insights highlight the importance of assessing eGFR change as a dynamic marker, offering a more comprehensive understanding of patient prognosis beyond single-point eGFR measurements.

Guiding Clinical Management and Monitoring Strategies

The assessment of eGFR change is instrumental in guiding clinical management and developing effective monitoring strategies for kidney health. Clinically, different definitions of kidney function decline, including continuous annual eGFR change, incident CKD, and rapid decline, are used to characterize various mechanisms of renal function alteration, with these definitions being featured in current guideline statements.^[1]By tracking these changes, clinicians can identify individuals at different stages of kidney disease progression, allowing for tailored interventions. For instance, monitoring for rapid eGFR decline helps select individuals who may benefit most from intensive management strategies aimed at slowing progression and mitigating associated risks.^[1] Accurate of eGFR change relies on standardized methodologies, such as calibrating serum creatinine measurements to national standards like NHANES data, to reduce inter-laboratory variability and improve precision.^[4] While eGFR estimation equations can be imprecise, particularly at higher GFR values, serial measurements over time provide a clearer picture of kidney function trajectories.^[1] Stratifying eGFR change by baseline CKD status, for example, distinguishing between those with and without baseline CKD, further refines risk assessment and informs targeted monitoring, as the rate and implications of decline can differ significantly based on initial kidney health.^[1]

Genetic Insights and Personalized Risk Stratification

Genetic factors play a substantial role in kidney function decline, offering avenues for personalized risk stratification and potentially novel prevention strategies. The heritability of eGFR change in the general population of European descent has been estimated at 38%, providing a strong rationale for investigating underlying genetic variants.^[1] Genome-wide association studies (GWAS) have identified specific genetic loci, such as UMOD, CDH23, and GALNTL5/GALNT11, which are associated with various kidney function decline phenotypes.^[1] The functional relevance of these novel loci is supported by experimental models, where knock-down of CDH23 and GALNTL5/GALNT11 in zebrafish nephrons increased susceptibility to nephrotoxic insults.^[1] Identifying individuals carrying these genetic predispositions can enable earlier identification of those at higher risk for accelerated kidney function decline, even before significant clinical manifestations. This genetic information could be integrated into personalized medicine approaches, allowing for more precise risk assessment and potentially earlier or more aggressive preventive measures. While these findings largely stem from general population cohorts, they provide fundamental insights into the mechanisms of kidney function decline, suggesting that genetic profiling could become a valuable tool in identifying high-risk individuals and informing tailored prevention strategies.^[1]

Frequently Asked Questions About Gfr Change

These questions address the most important and specific aspects of gfr change based on current genetic research.

---

1. My family has kidney problems. Will my kidney function decline faster?

Yes, there’s a significant genetic component to how quickly your kidney function changes. Research shows that about 38% of the variation in eGFR change can be inherited, meaning your family history plays a role in your personal risk. However, it’s not the only factor, and lifestyle can still have a big impact.

2. Can I really slow down my kidney decline just by changing my habits?

Absolutely, lifestyle changes can make a real difference. Early interventions like modifying your diet, exercising, and managing other health conditions can help slow down the progression of kidney function decline. This can reduce your risk of serious complications like heart disease.

3. Does my kidney function just naturally get worse as I get older?

Your kidney function can indeed decline as you get older, and rapid decline is particularly linked to adverse outcomes in older adults. However, the rate of decline varies greatly among individuals. Monitoring this change over time, rather than just a single , is key to understanding your personal kidney health trajectory.

4. Does my family’s ethnic background affect my kidney decline risk?

Yes, your ethnic background can influence your kidney decline risk. Most studies on the genetic factors for kidney function decline have focused on people of European descent, and the genetic architecture can differ significantly across various ethnic groups. This means that research in diverse populations is needed to fully understand these risks.

5. If my doctor says my GFR is good today, am I totally fine?

A single GFR is just a snapshot of your kidney health at that moment. What’s more critical is how your GFR changes over time. Your doctor will likely look at multiple measurements over years to see if there’s a decline, which gives much more insight into your kidney’s long-term health.

6. If my GFR drops just below 60, does that mean I have serious kidney disease?

Not necessarily, it’s a bit more complex. While a GFR below 60 ml/min/1.73m² is a definition of chronic kidney disease (CKD), in some general population studies, people with baseline CKD actually showed anincreasein GFR over time. This could mean stable disease or simply imprecision, not always active, progressive decline.

7. Why might my friend’s kidney function stay stable while mine gets worse?

There are unique genetic contributions that influence the rateat which kidney function declines, separate from the genes that affect your baseline kidney function. So, even if you and your friend start with similar kidney health, your individual genetic makeup can cause your function to change differently over time. Lifestyle factors also play a role.

8. Can eating healthier or exercising impact my kidney function decline?

Yes, making healthier choices like eating well and exercising can definitely help. These are considered crucial lifestyle modifications that can be part of an intervention strategy to slow the progression of kidney function decline. They contribute to overall health and can help manage co-morbidities that affect your kidneys.

9. Could my kidneys be declining even if I feel completely healthy?

Yes, it’s possible. Kidney function can decline gradually without noticeable symptoms, especially in its early stages. That’s why monitoring GFR change over time, typically with at least two measurements taken years apart, is so important. It helps identify issues before they become severe.

10. Will there be a test to predict my personal kidney decline risk?

Researchers are actively working on this! Understanding the genetic factors influencing GFR change is a key step towards improved risk prediction and personalized medicine approaches. The goal is to develop better strategies to prevent or slow the progression of chronic kidney disease, potentially through such predictive tests in the future.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Gorski M, et al. “Genome-wide association study of kidney function decline in individuals of European descent.” Kidney Int, 2015.

[2] Matsushita, K, et al. “Change in estimated GFR associates with coronary heart disease and mortality.”J Am Soc Nephrol, vol. 20, no. 12, 2009, pp. 2617-2624.

[3] Meguid El Nahas, A, and AK Bello. “Chronic kidney disease: the global challenge.”Lancet, vol. 365, no. 9456, 2005, pp. 331-340.

[4] Coresh, J. et al. “Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate.” Am J Kidney Dis, vol. 39, no. 5, 2002, pp. 920-929.

[5] Liu, C.T. et al. “Genetic association for renal traits among participants of African ancestry reveals new loci for renal function.” PLoS Genet. 2011; 7:e1002264.

[6] Böger CA, et al. “Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD.” PLoS Genet, 2011.

[7] Thorisson, G. A., A. V. Smith, L. Krishnan, and L. D. Stein. “The International HapMap Project Web site.” Genome Res, vol. 15, 2005, pp. 1592–1593.

[8] Rifkin, D. E., et al. “Rapid kidney function decline and mortality risk in older adults.”Arch Intern Med, vol. 168, no. 20, 2008, pp. 2212–2218.

[9] KDIGO. “KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.”Kidney International Supplements, vol. 3, 2013, pp. 1-150.

[10] Cheng, T. Y., et al. “Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan.”American Journal of Kidney Diseases, vol. 52, 2008, pp. 1051–1060.

[11] Shlipak, M. G., et al. “Rapid Decline of Kidney Function Increases Cardiovascular Risk in the Elderly.”Journal of the American Society of Nephrology, vol. 20, 2009, pp. 2625-2630.

[12] Turin, Tanvir C., et al. “Change in the estimated glomerular filtration rate over time and risk of all-cause mortality.”Kidney Int, vol. 83, no. 4, 2013, pp. 684–691.